Patient-Centered Approaches to Asthma Management (Long)
Question:
from Medscape: Highlights From the Annual Scientific Assembly: Patient-Centered Approaches to Asthma Management — Strategies for Treatment and Management of Asthma from Southern Medical Journal Posted 09/10/2002 R. Stokes Peebles, MD, and Tina V. Hartert, MD Introduction The purpose of this article is to review strategies for the outpatient treatment and management of asthma. In this review, we will examine the current recommendations for asthma treatment and focus on randomized, double-blind asthma pharmacotherapy trials published in 2001 that help us understand the role of the various asthma medications in the care of our patients. Although medical therapy is a cornerstone of asthma management, we will also detail current recommendations for nonpharmacologic approaches to asthma care and prevention. Before focusing on asthma therapy and management, it is first useful to review the current definition of asthma to provide a rationale for our recommendations for asthma treatment. The most recent National Asthma Education and Prevention Program outlines several components to the definition of asthma,[1] including (1) "asthma, whatever the severity, is a chronic inflammatory disorder of the airways"; (2) "in susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and cough, particularly at night and in the early morning"; and (3) that "atopy, the genetic predisposition for the development of an IgE-mediated response to common aeroallergens, is the strongest identifiable predisposing factor for developing asthma."[1] Obviously, other factors, such as tobacco smoke, air pollution, gastroesophageal reflux, and viral infections, can also contribute to inflammation of the airways and asthma symptoms; however, the fact that approximately 90% of children with asthma[2] and the majority of adult asthmatics have allergies[3] underscores the importance of allergic disease in asthma pathophysiology. Incumbent upon our recognition that inflammation and allergy are strongly related to asthma, minimizing the allergic inflammatory component in an overall asthma treatment strategy is, unfortunately, underutilized. Therefore, we propose a 4-step approach to asthma care: environmental control, pharmacologic management, immunotherapy, and vaccination. Environmental Control Many asthma patients can identify specific triggers that lead to the onset of chest tightness, wheezing, and shortness of breath. Such triggers might be seasonal, such as tree, grass, or weed pollens, or the triggers might be situational, such as exposure to animal dander.[4] In these instances, patients with mild symptoms when exposed to such allergens can either practice conscious allergen avoidance or increase medication use when exposure to known triggers is unavoidable. A subset of patients, however, experience seemingly random flares of asthma and are not aware of disease precipitants. Additionally, many patients experience perennial (year-round) symptoms and may or may not experience acute worsening of disease with specific triggers. It is these patients who are unaware of specific triggers or have perennial symptoms who may benefit most from allergen skin testing.[5] The presence of perennial symptoms does not rule out an allergic component to a person’s disease; instead, the allergic triggers are more likely to be from indoor allergens, such as dust mites, cockroaches, molds (such as Cladosporium, Penicillium, and Alternaria), or animal dander.[5] Allergen skin testing is a highly sensitive and specific method of identifying environmental factors that elicit the IgE-mediated degranulation of mast cells and basophils that are the cornerstone of the subsequent eosinophilic inflammation characteristic of the allergic response.[6] Allergen avoidance measures have been proven to be effective for both allergic rhinitis and asthma.[7] In fact, treating allergic rhinitis with environmental avoidance measures, as well as medical therapy, greatly improves asthma control. Without skin testing to prove that an allergic component may be a factor in asthma, however, patients and their families may needlessly spend considerable sums of money engaging in modification of the home environment that may make no difference in symptom control. Pharmacologic Management Since most asthma medications are given by inhalation, proper technique must be taught and, in most cases, a spacer should be used for inhaled medication delivery. Without proper technique and optimal medication delivery, no drug will be as effective as it could be, and the fault would not be necessarily be with the medication, but with the medical provider and patient for inadequate administration. The classification of asthma severity and the recommended treatment for each level of illness as recommended by the National Asthma Education Panel is outlined in Table 1.[1] For mild, intermittent asthma, the short-acting inhaled beta agonist remains the cornerstone of symptomatic control.[1] Beta agonists bronchodilate by relaxing smooth muscle that constricts the airways, and beta agonists are also reported to improve mucociliary function. The question of whether additional pharmacologic therapy is needed can be appropriately simplified by remembering the "rules of 2." If a patient has asthma symptoms and needs a short-acting beta agonist on more than 2 days per week, 2 nights per months, or needs more than 2 canisters of short-acting beta agonist per year, then a long-term controller medication is necessary.[1] A common error in asthma treatment is underestimating disease severity and not adding a controller medication when it is needed. Many randomized, double-blind studies indicate that inhaled corticosteroids are the initial controller medication of choice.[8-10] Other possible current choices for long-term controller medical therapy include leukotriene-receptor antagonists, such as montelukast or zafirlukast, long-acting beta agonists, such as formoterol or salmeterol, or the phosphodiesterase inhibitor, theophylline. The choice of inhaled corticosteroids as first-line controller therapy has been supported by numerous randomized, controlled trials looking at the impact of these medications on lung function and short-term morbidity, as well as observational studies showing an effect on both morbidity and mortality.[11-19] In addition, 3 studies published in 2001 have examined the efficacy of long-term controller regimens, comparing inhaled corticosteroids with alternative therapies.[8-10] Busse et al[8] examined the efficacy and safety of an inhaled steroid (low-dose fluticasone proprionate) compared with a leukotriene-receptor antagonist (montelukast) for first-line maintenance therapy in patients who were using short-acting beta agonists alone for persistent asthma. In this 24-week study of 533 patients 15 years of age, there was no placebo control. Compared with baseline, improvement in pulmonary function, need for beta-agonist rescue medication, asthma symptom scores, and nocturnal awakening was found in both the group using the inhaled steroid and the group using the leukotriene-receptor antagonist. The patients treated with the inhaled steroid had statistically and clinically significantly greater improvement in all of the aforementioned parameters, however, compared with those treated with montelukast.[8] Similarly, new evidence suggests that long-acting beta agonists should not be used as the sole first-line controller therapeutic agent. Lemanske et al[10] performed a randomized, controlled trial in 175 adolescent and adult asthmatics to determine whether the addition of a long-acting beta agonist might allow either elimination or dose reduction of inhaled corticosteroids. In this study, patients with persistent asthma who did not completely respond to 6 weeks of therapy with an inhaled corticosteroid (triamcinolone) were randomized to treatment with a long-acting beta agonist (salmeterol) or placebo, after which a trial of reduction in the inhaled steroid dose was attempted. Those patients treated with the long-acting beta agonist were able to reduce the corticosteroid dose safely, but there was an unacceptably high rate of treatment failure in the salmeterol group when inhaled steroids were totally discontinued.[10] Lazarus et al[9] tested a similar question in a trial designed to examine the effectiveness of a long-acting beta agonist (salmeterol) versus an inhaled steroid (triamcinolone) for controller therapy. In that study, 166 patients with persistent asthma that was well controlled on an inhaled steroid were randomized to either continue their inhaled steroid or switch to the long-acting beta agonist. There were more treatment failures, a greater increase in eosinophilic inflammation, and increased sputum tryptase level in those randomized to the long-acting beta agonist, compared with those who continued taking the inhaled steroid.[9] These last 2 studies suggest that patients with persistent asthma that is controlled by inhaled corticosteroids cannot be switched to monotherapy with a long-acting beta agonist without the risk of losing asthma control.[9,10] Thus, inhaled corticosteroids are preferred over long-acting beta agonists and leukotriene-receptor antagonists for controller therapy. The choice for additional therapy when a patient’s asthma is not well controlled on a substantial dose of inhaled corticosteroids is more complex. Nelson et al[20] compared the efficacy and safety of a combination of inhaled steroid and long-acting beta agonist (fluticasone and salmeterol) with an inhaled steroid and a leukotriene-receptor antagonist (fluticasone and montelukast). In this multicenter, double-blind, double-dummy, parallel-group 12-week study, patients were enrolled who remained symptomatic on a low dose of inhaled corticosteroid. All patients were then treated for 12 weeks with the same dose of inhaled corticosteroid, … read more »
Response:
- Hide quoted text — Show quoted text – from Medscape: Highlights From the Annual Scientific Assembly: Patient-Centered Approaches to Asthma Management — Strategies for Treatment and Management of Asthma from Southern Medical Journal Posted 09/10/2002 R. Stokes Peebles, MD, and Tina V. Hartert, MD Introduction The purpose of this article is to review strategies for the outpatient treatment and management of asthma. In this review, we will examine the current recommendations for asthma treatment and focus on randomized, double-blind asthma pharmacotherapy trials published in 2001 that help us understand the role of the various asthma medications in the care of our patients. Although medical therapy is a cornerstone of asthma management, we will also detail current recommendations for nonpharmacologic approaches to asthma care and prevention. Before focusing on asthma therapy and management, it is first useful to review the current definition of asthma to provide a rationale for our recommendations for asthma treatment. The most recent National Asthma Education and Prevention Program outlines several components to the definition of asthma,[1] including (1) "asthma, whatever the severity, is a chronic inflammatory disorder of the airways"; (2) "in susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and cough, particularly at night and in the early morning"; and (3) that "atopy, the genetic predisposition for the development of an IgE-mediated response to common aeroallergens, is the strongest identifiable predisposing factor for developing asthma."[1] Obviously, other factors, such as tobacco smoke, air pollution, gastroesophageal reflux, and viral infections, can also contribute to inflammation of the airways and asthma symptoms; however, the fact that approximately 90% of children with asthma[2] and the majority of adult asthmatics have allergies[3] underscores the importance of allergic disease in asthma pathophysiology.
I’m surprised they didn’t mention that chronic sinusitis can trigger asthma symptoms–given that chronic sinusitis now afflicts many millions of Americans. And given that for many folks (like myself), it’s proven to be incurable, and thus becomes a chronic trigger of lower respiratory problems. Many asthma specialists have had to become knowledgeable at treating the sinus symptoms of their asthma patients. — Steven D. Litvintchouk
Categories:
